eGene Plan to Launch Complete Solution for Fast and Low-Cost Bird Flu Screening Through Distribution Agreement With Veredus Labs, Singapore for Its AIV-H5N1 PCR Kit Using eGene’s HDA-GT12 System
eGene Inc. (OTCBB:EGEI), developer of a revolutionary high-performance genetic analysis technology, today announced that it plans to launch a complete solution for fast and low-cost bird flu screening by entering into a distribution agreement with Veredus Labs, Singapore for AIV-H5N1 PCR Kit Using eGene’s HDA-GT12 System.
Ming S. Liu, CEO of eGene, made the announcement noting: “We are entering an agreement with Veredus Labs, Singapore to apply its AIV-H5N1 PCR kit with our HDA-GT12 system. Our previous testing results indicated that the HDA system, in combination with this single step RT-PCR assay, is a simple and sensitive assay for H5N1 avian influenza detection that can detect as few as 10 copies of the viral RNA. A total of 96 samples can be analyzed in less than 50 minutes. Initially, we believe a fast, sensitive and low-cost analysis to identify the contamination of the viral RNA in the poultry market can be one of the key factors to prevent the mass spread of the virus.”
About Veredus Labs.
Veredus Laboratories is a molecular diagnostics company in Singapore engaged in the development, commercialization and manufacturing of diagnostic assays for diseases. The company focus is to aid patients via faster, more precise, and better diagnostics to enable pathogen-specific treatment of infectious diseases at the earliest detectable stage.
About eGene Inc.
eGene developed the HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels). The system analyzes the genetic fingerprints of living organisms. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of RNA in gene expression market. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize biomolecules including DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management’s current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to publicly release any revision, which may be made to reflect events or circumstances after the date hereof.